New York State Teachers Retirement System lowered its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 5.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 145,558 shares of the company's stock after selling 8,746 shares during the quarter. New York State Teachers Retirement System owned about 0.08% of Catalent worth $8,816,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of CTLT. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent during the second quarter worth $42,000. Longfellow Investment Management Co. LLC grew its stake in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after acquiring an additional 212 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in Catalent by 1,400.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company's stock valued at $91,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Catalent by 456.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,833 shares of the company's stock valued at $159,000 after purchasing an additional 2,324 shares in the last quarter.
Insider Buying and Selling at Catalent
In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.31% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on CTLT shares. Robert W. Baird restated a "neutral" rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair restated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. StockNews.com started coverage on Catalent in a report on Saturday, October 12th. They set a "hold" rating on the stock. Finally, Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $59.83.
Get Our Latest Research Report on Catalent
Catalent Stock Performance
NYSE:CTLT traded down $0.04 during midday trading on Monday, reaching $58.69. 1,995,605 shares of the company traded hands, compared to its average volume of 2,040,685. The firm has a market capitalization of $10.65 billion, a price-to-earnings ratio of -10.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.16. The company has a fifty day moving average price of $60.06 and a 200 day moving average price of $57.98. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. Catalent, Inc. has a twelve month low of $32.38 and a twelve month high of $61.20.
Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, analysts expect that Catalent, Inc. will post 0.95 EPS for the current fiscal year.
About Catalent
(
Free Report)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Featured Articles
Before you consider Catalent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalent wasn't on the list.
While Catalent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
